Beam Therapeutics is a biotechnology company committed to creating a new class of precision genetic medicines based on our proprietary base editing technology, with a vision of providing life-long cures to patients suffering from serious diseases.
Recent Press Releases
November 12, 2021
Beam Therapeutics Reports Preclinical Data Highlighting Multiplex Base Editing Approach to Create Anti-CD5 CAR T-cell Investigational Therapies for T-Cell Malignancies
November 11, 2021
November 8, 2021
Beam Therapeutics Provides Business and Pipeline Updates and Reports Third Quarter 2021 Financial Results